GLP-1 therapies have expanded beyond diabetes and obesity treatment, displaying vascular and potential mental health benefits ...

While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS - - SENTRY ...

From 2016 to 2023, aggregate absolute operational emissions from listed companies continued to rise, as reductions in ...

Cervical cancer is not a scam, but the gap between India’s under‑reported mortality data and global estimates exposes a ...

Results from the phase 3 SENTRY trial show that selinexor plus ruxolitinib significantly reduced spleen volume in patients with myelofibrosis.

At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow.

COVID-19 school closures are projected to reduce educational attainment and weaken intergenerational mobility, with children ...

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart ...

In This Article, You'll Discover: What exactly is Burn Slim and why is it gaining momentum in 2026? How does the Burn Slim fo ...

Background Transcatheter aortic valve replacement (TAVR) has already been recommended for some high-risk patients with aortic ...

CBIZ(NYSE:CBZ), a major business services provider, reported insider selling amid a year of sharp share price declines. On March 10, 2026, Benaree Pratt Wiley, Director of CBIZ, reported the indirect ...

Cochlear shares (ASX:COH) fell to their lowest level in years, hitting A$160 before closing at A$161.38, as a revenue ...